The UK and US have signed a major trade agreement that will preserve zero levies on British drug shipments entering the American market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to boost spending on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that tariffs on these vital goods will stay at nothing for a period of three years.
This deal follows previous warnings to hike tariffs on patented drug products, with figures floated reaching one hundred percent.
"This deal with the Britain strengthens the worldwide climate for new treatments and establishes much-needed balance to transatlantic pharmaceutical trade," a statement noted.
Trade Significance
Pharmaceuticals are one of the UK's biggest export categories to the America, which is clearly the largest destination for large companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months to the end of the third quarter, the UK sold drugs valued at £11.1bn to the US. This value made up a significant portion of British export trade in that span.
"This deal secures work, stimulates investment and paves the way for the UK to establish itself as a international leader for medical research," a minister commented.
Specific UK Commitments
The agreement involves several key commitments from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a goal to raise total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The amount drug companies must return to the NHS to prevent overspending will be limited at fifteen percent. In the past, repayments were more than twenty percent.
Recent Tensions
This agreement comes amid a protracted dispute between the drug companies and the British authorities over spending levels and NHS adoption.
The disagreement were heightened by claims that American customers were charged several times more for the same drugs than people in the UK and Europe.
Recently, several major drug company projects in the UK have been delayed or cancelled, while substantial funding commitments have been announced toward projects in the United States.
One official stated that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a percentage of its resources over the past decade.
